Table 3.
Clinicopathological characteristics of validation patients undergoing potentially curative resection of colorectal cancer and cancer-specific survival (n = 801)
| Nuclear pERK1/2 | Cytoplasmic pERK1/2 | Combined nuclear pERK/p38 score | Combined cytoplasmic pERK/p38 score | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weak (n = 327) | Strong (n = 474) | p | Weak (n = 379) | Strong (n = 422) | p | Bothweak/one strong (n = 427) | Both strong (n = 374) | p | Both weak/one strong (n = 536) | Both strong (n = 265) | p | |
| BRAF status | ||||||||||||
| Wild type | 265 (84) | 352 (75) | 0.003* | 306 (83) | 331 (75) | 0.009* | 344 (83) | 273 (74) | 0.002* | 416 (80) | 201 (76) | 0.228 |
| Mutant | 50 (16) | 115 (25) | 63 (17) | 102 (25) | 70 (17) | 95 (26) | 103 (20) | 62 (24) | ||||
| Mismatch repair status | ||||||||||||
| Competent | 529 (80) | 405 (86) | 0.01* | 302 (81) | 362 (86) | 0.032* | 343 (81) | 321 (86) | 0.065 | 439 (83) | 225 (85) | 0.526 |
| Deficient | 66 (20) | 63 (14) | 72 (19) | 57 (14) | 78 (19) | 51 (14) | 89 (17) | 40 (15) | ||||
| Age | ||||||||||||
| <65 | 108 (33) | 148 (31) | 0.591 | 125 (33) | 131 (31) | 0.557 | 140 (33) | 116 (31) | 0.592 | 184 (34) | 72 (27) | 0.039* |
| >65 | 219 (67) | 326 (69) | 254 (67) | 291 (69) | 287 (67) | 258 (69) | 352 (66) | 193 (73) | ||||
| Serum CRP | ||||||||||||
| Normal | 137 (51) | 222 (59) | 0.03* | 165 (55) | 194 (57) | 0.595 | 191 (53) | 168 (59) | 0.172 | 256 (56) | 103 (54) | 0.547 |
| High | 133 (49) | 152 (41) | 137 (45) | 148 (43) | 167 (47) | 118 (41) | 197 (44) | 88 (46) | ||||
| mGPS | ||||||||||||
| 0 | 138 (51) | 224 (59) | 0.069 | 168 (55) | 194 (57) | 0.776 | 192 (53) | 170 (59) | 0.243 | 259 (57) | 103 (54) | 0.192 |
| 1 | 89 (33) | 97 (26) | 95 (31) | 91 (26) | 112 (31) | 74 (26) | 135 (29) | 51 (27) | ||||
| 2 | 45 (16) | 55 (15) | 42 (14) | 58 (17) | 57 (16) | 43 (15) | 63 (14) | 37 (19) | ||||
| Tumour-infiltrating lymphocytes | ||||||||||||
| Absent | 242 (76) | 368 (79) | 0.297 | 293 (79) | 317 (77) | 0.527 | 313 (76) | 297 (81) | 0.061 | 398 (76) | 212 (82) | 0.078 |
| Present | 75 (24) | 95 (21) | 77 (21) | 93 (23) | 101 (24) | 69 (19) | 123 (24) | 47 (18) | ||||
| Klintrup–Makinen grade | ||||||||||||
| Weak | 217 (68) | 317 (68) | 0.966 | 257 (69) | 277 (67) | 0.514 | 276 (66) | 258 (70) | 0.31 | 362 (69) | 172 (66) | 0.451 |
| Strong | 102 (32) | 150 (32) | 115 (31) | 137 (33) | 140 (34) | 112 (30) | 164 (31) | 88 (34) | ||||
| TNM stage | ||||||||||||
| 1 | 45 (14) | 65 (14) | 0.567 | 51 (14) | 59 (14) | 0.152 | 61 (14) | 49 (13) | 0.996 | 68 (13) | 42 (16) | 0.052 |
| 2 | 152 (46) | 234 (49) | 171 (45) | 215 (51) | 201 (47) | 185 (50) | 252 (47) | 134 (51) | ||||
| 3 | 130 (40) | 175 (37) | 157 (41) | 148 (35) | 165 (39) | 140 (37) | 216 (40) | 89 (33) | ||||
| Venous invasion | ||||||||||||
| Absent | 218 (67) | 318 (67) | 0.901 | 254 (67) | 282 (67) | 0.954 | 281 (66) | 255 (68) | 0.476 | 353 (66) | 183 (69) | 0.364 |
| Present | 109 (33) | 156 (33) | 125 (33) | 140 (33) | 146 (34) | 119 (32) | 183 (34) | 82 931) | ||||
| Proliferation Index | ||||||||||||
| Low | 146 (45) | 213 (45) | 0.943 | 169 (45) | 190 (46) | 0.835 | 197 (47) | 162 (44) | 0.412 | 235 (44) | 124 (47) | 0.483 |
| High | 178 (55) | 259 (55) | 208 (55) | 227 (54) | 226 (53) | 209 (56) | 295 (56) | 140 (53) | ||||
*Significant difference p < 0.05